Symbol not found

NASDAQ:EWTX   00:00AM GMT
0.00
0.00 (0.00%)
Earnings Announcements

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results

Published: 08/04/2022 12:55 GMT
Edgewise Therapeutics Inc (EWTX) - Edgewise Therapeutics Reports Second Quarter 2022 Financial Results.
Cash, Cash Equivalents and Marketable Securities of $248.4 Million As of June 30, 2022.
Initiated Phase 2 Trial in Bmd; Expect to Start Phase 2 Trial in Duchenne Muscular Dystrophy (dmd) in 2022.
Net Loss and Net Loss per Share for Q2 of 2022 Was $16.1 Million Or $0.32 per Share.
Anticipatesits Cash Resources on Hand Will Be Sufficient to Support Its Planned Growth and Operations Through End of 2024.
Q2 Earnings per Share View $-0.32 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.37

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.41

More details on our Analysts Page.